Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors

Neoadjuvant therapy that combines abiraterone acetate plus prednisone (AAP) and leuprolide prior to radical prostatectomy significantly reduces tumor size in... Read More

Dementia Not Linked to ADT for Prostate Cancer

New research may ease concerns that androgen deprivation therapy (ADT) contributes to dementia in patients with prostate cancer (PCa). Read... Read More

Study: Private Payer Coverage of Prostate MRI Lagging

Prostate magnetic resonance imaging (MRI) has becoming increasingly important in diagnosing and managing prostate cancer (PCa), but private payer coverage of prostate... Read More

The Potential Role for PARP Inhibitors in Prostate Cancer

Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for... Read More

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

PSA doubling time (PSADT) can predict oncologic and survival outcomes among men who receive brachytherapy for localized prostate cancer (PCa),... Read More

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Selected patients at elevated risk for biochemical recurrence of prostate cancer (PCa) following radical prostatectomy (RP) may benefit from tailored... Read More

Study Supports Prostate Cancer Active Surveillance for Younger Men

Younger men on prostate cancer (PCa) active surveillance (AS) are at lower risk of Gleason score upgrading and pathologic progression... Read More

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

Reducing the duration of androgen deprivation therapy (ADT) from 36 months to 18 months in men with localized high-risk prostate... Read More

PET/CT May Improve Imaging of Recurrent Prostate Cancer

Positron emission tomography (PET)-based imaging may offer a promising alternative to conventional imaging for characterizing the true extent of disease... Read More

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

Aggressive therapy with curative intent appears to be highly successful in men with Gleason score 10 prostate cancer, according to... Read More

1 2 3 10